Dallas, Texas (PRWEB) May 28, 2014
The market for cell-based assays is driven by the preference over biochemical assays and animal models and the emergent 3D cell-based assay techniques in cell-based assays.
There has been a substantial rise in the costs to develop a new drug in recent years. This is specially observed when a new compound enters animal testing. The use of animals in experimentation is becoming dearer, due to limitations such as high costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues and legal issues associated with it. Moreover the traditional biochemical assays also posses many limitations. To counteract these issues there has been a paradigm shift towards the use of cell-based assays.
Company Profiles included in this study are Becton, Dickinson And Company, Cell Signaling Technology, Cisbio Bioassays (Argos Soditic), Danaher Corporation, Discoverx, Emd Millipore (A Subsidiary Of Merck Kgaa), Ge Healthcare (Subsidiary Of General Electric Company), Life Technologies (Thermo Fisher Scientific), Perkinelmer, Inc. And Promega Corporation.
Request a Sample at http://www.reportsnreports.com/contacts/RequestSample.aspx?name=283974.
The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and assay kits; where most of the innovation is taking place. Drug discovery was the most prominent application of cell-based assays. Within drug discovery, lead identification and optimization accounted for the largest share in 2013. With respect to end users, the pharmaceutical and biotechnology companies commanded the largest share in 2013. These industries are focusing on screening extensive libraries of compounds that could become leads for potential drug candidates. The screening process has helped the pharmaceutical companies to run more cost and time efficient methods.
For accurate results, the low cost label-free technology in cell based assays has emerged as a momentous technology that has been driving the growth of cell-based assay market. With the advancement in the cell stem cell culture, induced pluripotent stem cells will be emerging in near future. With the increasing demand of emergent 3D cell-based assay, it is estimated to be the fastest growing technology in the next five years.
North America accounted for the largest share of the global cell-based assay market in 2013. The presence of a large number of market players along with government funding for drug discovery and increasing number of public-private partnerships are the factors driving the North American cell-based assay market. Countries such as India and China serve as new revenue pockets for the cell-based assay market. Healthcare reforms, government initiatives, growing awareness and increasing investments in drug discovery are encouraging the rising acceptance and adoption of the cell-based assay technology in these regions. The emerging countries in Asia such as China and India will register high growth in the coming years; this can be attributed to the low development costs offered by these nations. Moreover, clinical research organizations are growing at fastest rate and more inclined to set their pace in these nations.
Inquire for discount at http://www.reportsnreports.com/contacts/Discount.aspx?name=283974.
The grey areas while estimating the market size was the overlapping nature of the products and technology while segregating them based on evaluation of endpoints involved. As there is a thin line between products and technology used, both were included while estimating the patient monitoring market.
From an insight perspective, this research report focuses on the qualitative data, market size, share, growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of cell-based assay market, high-growth regions, and the initiatives of respective governments.
The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the cell-based assay market, product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.
Place a direct purchase order at http://www.reportsnreports.com/Purchase.aspx?name=283974.
Table of Contents
2 Executive Summary
3 Premium Insights
4 Market Overview
5 Cell-Based Assays Market, By Product
6 Cell-Based Assays Market, By Application
7 Cell-Based Assays Market, By End User
8 Cell-Based Assays, By Geography
9 Company Landscape
10 Company Profiles
List of Tables
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.